search
Highlights
     // . //  Oliver Wyman Health //  Managing Uncertainties In Cell And Gene Therapy Supply Chain

    Managing Uncertainties In Cell And Gene Therapy Supply Chain

    Image

    Since the infrastructure needed to support cell and gene therapies is so complex, companies must assess supply chain issues early, even before entering human studies.

    Tobias Handschuh and Matthew Lakelin

    2 min read

    Table of Contents

      Begin with the end in mind. That’s Matthew Lakelin’s advice for companies aiming to bring cell and gene therapies to market.

      Because the infrastructure needed to support cell and gene therapies is so complex, companies must consider supply chain issues very early on, even before they enter human studies, said Lakelin, Vice President of Scientific Affairs at TrakCel, a company that helps manage all components of the cell and gene therapy supply chain.

      For instance, blood, tissue, and other materials used in cell and gene therapy may have time and temperature constraints. Any misstep in the supply chain means starting over. Those factors will impact where manufacturing plants are built, which logistics companies are involved in transporting materials, how far a clinic or treatment site is from the plant and the patient.

      In this video, Lakelin and Oliver Wyman’s Tobias Handschuh detail what’s required to ensure that cell and gene therapies can get to patients in a safe, efficient, and timely manner. The interview was recorded at the Oliver Wyman Health and Life Sciences Innovation Forum.

      8:08

      Authors

      Humira Biosimilars Could Reshape The Market

      There’s been mixed adoption of biosimilars in the US, especially compared to Europe. That could all change as several Humira biosimilars prepare to launch.

      Ensuring Seamless Transition From Medicaid To ACA Enrollment

      Neighborhood Health Plan of Rhode Island has a robust outreach and education effort to close gaps in coverage.

      FDA Approval Is A Big Step But Alzheimer’s Drugs Face Other Hurdles

      Full FDA approval of Leqembi means Medicare coverage for a breakthrough therapy. Now we need a suitable infrastructure for diagnosis, treatment, and monitoring.

      Biosimilar Makers Carve New Path Via Contracting, Partnering

      More than a year after losing exclusivity, Humira still holds a large market share. Biosimilar manufacturers are testing new contracting methods to catch up.